Jeremy Abramson, MD, director of the Jon and Jo Ann Hagler Center for Lymphoma at the Massachusetts General Hospital Cancer Center, shared his take on the potential benefits of chimeric antigen receptor (CAR) T-cell therapy in earlier lines of treatment.
Earlier administration of chimeric antigen receptor (CAR) T-cell therapy may be ideal in large B-cell lymphoma, said Jeremy Abramson, MD, associate professor of medicine at Harvard Medical School and director of the Jon and Jo Ann Hagler Center for Lymphoma at the Massachusetts General Hospital Cancer Center.
Transcript
How do clinicians decide whether to use CAR T-cell therapy early or after another therapy?
Well, I think the ultimate [question] is where does it work the best? And CAR T-cell therapy seems to work best the sooner you give it. We initially had CAR T cells approved in the third line or later setting for large B-cell lymphoma, but now between the ZUMA-7 and the TRANSFORM trials, we see very clearly that earlier CAR T cells are better than giving platinum-based chemotherapy and high-dose chemotherapy and saving that in reserve. We saw that reflected in the in the crossover population on the TRANSFORM trial, where patients were randomized to standard of care and then crossed over to receive liso-cel when standard of care failed, had lower rates of complete response, progression-free, and event-free survival than patients who is least three received liso-cel in a second line setting. We saw data presented yesterday at the ASH Annual Meeting from the ZUMA-7 trial that looked at patients on the standard-of-care arm of that trial, who subsequently received a commercial CAR T-cell [therapy] after failure of standard of care. And they saw identical findings to what we saw, which is lower rates of complete response and progression-free survival for patients who received axi-cel as a third-line treatment rather than patients randomized to receive it in the second-line setting.
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More
What We’re Reading: HHS' Funding Flat; Mifepristone Safety; Insulin Shortage
March 25th 2024Flat funding for Health and Human Services (HHS) leaves critical health initiatives stagnant; Supreme Court weighs tightening regulations on abortion pill; manufacturing delay sparks access concerns for insulin medication.
Read More